|Online ISSN : 2349-8080
Issues : 12 per year
Publisher : Excellent Publishers
Email : firstname.lastname@example.org
2Department of Chemistry, Jadavpur University, Raja S C Mallick Road, Kolkata-700 032, West Bengal, India
3Department of Physics, Jadavpur University, Raja S C Mallick Road, Kolkata-700 032, West Bengal, India
Haematological disorders and related complications are very common phenomenon against hazardous chemicals. Alteration of hematologic parameters disrupts the body’s normal homeostasis. There is a worldwide need to develop a safe and symptomatic medication which controls the haematological complications. Healthy adult Swiss albino mice were assigned to four groups of six mice each according to their weights. Group-I serve as control, Group-II received multi herbal formulation (AKSS16-LIV01) 400 mg/kg/day, Group-III received carbon tetrachloride (CCl4) 1 ml/kg-bw and Group-IV received CCl4 along with AKSS16-LIV01 (400 mg/kg). Blood samples were collected from the retro orbital plexus of each animal to determine various blood parameters and liver transaminase. Administration of carbon tetrachloride (CCl4) showed decline body weight, food consumption and water intake in mice whereas treatment with multi herbal formulation (AKSS16-LIV01) normalized the same as compared with untreated animals. Treatment with CCl4 (Group-III) decline the packed cell volume (PCV), haemoglobin (Hb), means cell volume (MCV), means cell hemoglobin (MCH) and greater the white blood cell (WBC) compared with control. Pre-treatment with AKSS16-LIV01 significantly (p<0.001) increased the PCV, Hb, MCH, MCH and decreased WBC count in experimental animals as compared with CCl4 treated group. On the other hand elevated liver transaminase enzymes i.e. AST and ALP by CCl4 was restored with administration of multi herbal formulation (AKSS16-LIV01). Chronic administration of CCl4 indicated adverse effects on haematologic parameters upon experimental animals. Simultaneous administration with newly developed novel multi herbal formulation (AKSS16-LIV01) was able to ameliorate these adverse effects and may be a potent drug in future which controls the blood related medical complications against the toxicants.